⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159674 | 0.91 | — | — | |
| SCHEMBL199821 | 0.91 | — | — | |
| SCHEMBL21623666 | 0.91 | — | — | |
| SCHEMBL383406 | 0.91 | — | — | |
| SCHEMBL1369276 | 0.83 | — | — | |
| SCHEMBL11788894 | 0.83 | — | — | |
| SCHEMBL1367575 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL17925355 | 0.83 | — | — | |
| SCHEMBL1370855 | 0.83 | — | — | |
| SCHEMBL2320571 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105018088-A | Silicate-based rare-earth ion doped visible-ultraviolet up-conversion luminescent material, and preparation method and application thereof | UNIV HEBEI | 2015-11-04 | — | — | CN | claimed |
| CN-105018088-A | Silicate-based rare-earth ion doped visible-ultraviolet up-conversion luminescent material, and preparation method and application thereof | UNIV HEBEI | 2015-11-04 | — | — | CN | disclosed |
| EP-1778637-B1 | FKBP-binding composition and pharmaceutical use thereof | AVENTIS PHARMA INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7777042-B2 | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100063065-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| EP-1937647-A1 | CONDENSED PYRAZOLE DERIVATIVES AS PPAR AGONISTS II | Inpharmatica Limited (GB) | 2008-07-02 | — | — | EP | disclosed |
| EP-1937663-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | Inpharmatica Limited (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007036730-A9 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LTD (GB) | 2008-06-19 | — | — | WO | disclosed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| EP-1778637-A2 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | Aventis Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2007036730-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007036727-A1 | CONDENSED PYRAZOLE DERIVATIVES AS PPAR AGONISTS II | INPHARMATICA LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2006012256-A2 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20040106538-A1 | Regulators of PPARdelta (beta) and their use in the treatment of obesity and insulin resistance | HARIHARAN NARAYANAN (US) | 2004-06-03 | — | — | US | disclosed |
| US-6677298-B2 | PROTEIN ANTAGONIST; ANTIDIABETIC AGENTS, ANTILIPEMIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-20020042359-A1 | Regulators of PPARdelta (beta) and their use in the treatment of obesity and insulin resistance | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-11 | — | — | US | disclosed |